As 2018 begins, STAT reporters are taking a look at the stories they’re most eager to track this year. Find all our “three to watch” series here

Biotechnology is an ever-evolving field, with advances coming at us at a breakneck pace.

And this past year was historic, as it saw some cutting-edge biotech drugs move from the lab to the clinic. The first-ever gene therapy was approved by the Food and Drug Administration to treat a pediatric blood cancer. The CAR-T drug, called Kymriah and marketed by Novartis (NVS), is made by genetically reengineering a patient’s own immune cells to target his or her cancer. Two other gene therapies quickly followed suit: another CAR-T drug from Gilead Sciences (GILD) and a drug from Spark Therapeutics (ONCE) that corrects a rare inherited form of blindness.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy